[Treatment of scleroderma].
D000629:Aminopropionitrile / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002738:Chloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009640:Norethindrone / Q000009:adverse effects / Q000627:therapeutic use*; D011374:Progesterone / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats; D012594:Scleroderma, Localized / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy*
D005938:Glucocorticoids; D000629:Aminopropionitrile; D011374:Progesterone; D002738:Chloroquine; D009640:Norethindrone
Tratamiento de la esclerodermia.